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We thank Hemminki and Snellman (2002) for their
interest in our studies and we are pleased to be able
to clarify the issues they raise. The main purpose of
our study (Sheehan et al 2002), as indicated by the
title of the paper, was to determine the photoprotec-
tive properties of induced pigmentation by solar
simulated radiation (SSR) in skin types II and IV.
We used individual biological [just perceptible min-
imal erythemal doses (MED)] dose increments rather
than ®xed physical (J/cm2) doses because individual
exposure in real-life is determined by sun-sensitivity.
This is supported by recent studies, in which per-
sonal exposure has been electronically monitored
over 114 days, that show that skin types IV have
about 40% more solar UVR-exposure than skin types
II (Thieden E. & Wulf H.C., personal communica-
tion).
P
hotoprotection against DNA photodamage from 2 MED
challenge dose of SSR was assessed one week after the
last tanning treatment because we expected, based on
work in our laboratory (Young et al, 1996) and that of
Hemminki (Bykov et al, 1999), to ®nd that the majority
of the thymine dimers accrued during the tanning protocol would
have been removed by that time.
The essential point of Fig 3 (Sheehan et al 2002) is that there was
a highly signi®cant reduction of thymine dimers in skin type IV one
week after the last treatment, but a trivial nonsigni®cant reduction
in skin type II. In support of our observations, we would like to
have been able to cite Hemminki et al (2002), who show the
persistence of 2.4% and 8.9% of thymine dimers in skin types I and
IV, respectively, for up to three weeks after a single SSR exposure,
but unfortunately this paper was published in April 2002, one
month before the publication of our paper that was accepted for
publication in October 2001. Our study shows the persistence of
dimers in skin type II for one week after two weeks daily (Mon-Fri)
SSR exposure and, to a much lesser extent, the persistence of
dimers in skin type IV. Thus, both groups, using different
techniques and irradiation protocols, show that epidermal thymine
dimers persist.
Hemminki and Snellman (2002) comment on the lack of a dose±
response effect in skin type IV in Fig 2(a) (Sheehan et al 2002). An
analysis of the individual data shows that all skin type II volunteers
show a dose±response, whereas this is only seen in 4/6 of skin type
IV volunteers, which reduces the mean. Nonetheless, we have
observed this plateau effect with SSR before (Young et al, 1996)
and fully recognize that immunohistochemical techniques are
semiquantitative. There are two dose±response curves for thymine
dimers in publications from Hemminki's laboratory. One, in vivo
with SSR (Bykov et al, 1998a), does indeed show a very linear
dose±response but the other, in skin explants with maximum UVC
dose of about 2±3 MED (Bykov and Hemminki, 1995), shows an
aysymptotic response similar to ours, even though a straight line has
been ®tted through the data.
Hemminki and Snellman (2002) contend that antibody tech-
niques are invalid and suggest that our results may be due to
nonspeci®c background staining. All sections were stained as one
batch because we are aware that different staining runs may give
different results. We have negative controls for no SSR exposure in
all cases, and we ®nd that the antibody we used shows speci®c and
discrete nuclear staining with virtually no background staining at
all. For example, see Fig 4(a) in Young et al (1998a) that shows
dimer positive nuclei in the supra-basal nuclei of the epidermis after
290 nm but no staining at all in the basal layer of the same section.
In contrast Fig 4(b) and 4(c) show staining throughout the
epidermis and dermis after irradiation with 300 nm.
This differential staining on the same skin section shows the great
advantage of localizing DNA photodamage within the epidermis,
dermis, and even within speci®c cell types such as melanocytes
(Young et al, 1998b). The techniques described by Hemminki and
Snellman (2002) require the disruption of the epidermis and are
totally unable to provide any information whatsoever on localiza-
tion or cell type speci®city. For example, persistent dimers in the
suprabasal epidermis are unlikely to have any biological conse-
quence. It is our view that the understanding of the biological
signi®cance of DNA repair in human skin is best served by the use
of a variety of different techniques. Hemminki and Snellman
recognize this because as coauthors of Xu et al (2000a), they state
``Because melanocytes only make up 5%-10% of the cell population
only immunohiostochemical techniques would allow a direct
assessment of DNA damage and repair in melanocytes in situ``
(Young et al, 1996, 1998a).
Hemminki and Snellman's (2002) argument that our data are
invalid also assumes that the DNA repair response after repeated
exposure is the same as the response after a single exposure, which
does not allow for the possibility of modi®cation of the repair
response by repeated exposure. In fact, various factors are likely to
be important and the level of DNA photodamage at a given time is
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likely to be a complex balance of individual repair at 24 h,
apoptosis, necrosis, the addition of damage from a subsequent
exposure 24 h later, epidermal proliferation, the loss of DNA
damage through desquamation that is likely to be accelerated by
repeated SSR exposure, as evidenced by stratum corneum thick-
ening, and induced photoprotection. The dynamics of these
complex interactions are very likely to be time-dependent, and it
is possible that a steady homeostatic state may be reached.
We note that Bataille et al (2000) (of which Hemminki is the
senior author) published a study in which epidermal DNA
photodamage was assessed in the noninvolved skin of psoriatics
undergoing UVB phototherapy. The abstract of this paper states
``Overall, the levels of TT = T and TT = C reached a plateau at
three exposures and were found to decrease with subsequent
exposures despite increasing UVB doses'' (there were no data from
a single exposure) and ``No association was found between
challenge dose of UVB and photoproduct yield in this study.''
The arguments Bataille et al (2000) used to explain their results are
largely similar to those that we give in the paragraph above.
In support of our observations and conclusions we refer to a
recently completed similar study in skin type II with a different
thymine dimer antibody (Kamiya Biomedical Company, Seattle,
WA), and in which we counted dimer positive cells in different
epidermal layers as opposed to mean optical density per nucleus.
This study has given virtually identical results to those of Sheehan et
al (2002). However, it also included a biopsy taken at the end of
week 1 (5 3 0.65MED) which showed two-fold increase of basal
cell dimer positive nuclei when compared with a single 0.65MED
exposure, but at the end of week 2 (10 3 065MED) the number of
dimer positive cells was similar to that of a single 0.65MED dose.
Interestingly, this re¯ects the skin type II erythema time-course of
Fig 1a in Sheehan et al (2002) which shows an increase over the
®rst week with a reduction in a plateau in week two. In this context
it is worth noting that xeroderma pigmentation (XP) patients,
known to have poor DNA repair, show persistent erythema (Berg
et al, 1998).
We have a signi®cant amount of as-yet unpublished data which
shows that acute SSR responses may not predict the cellular,
apoptotic, and immunological responses from repeated SSR
exposure, and that an acute response may be different on untreated
skin compared with repeatedly irradiated skin, and that this
difference varies considerably with endpoint. We believe that
skin has varying adaptive responses other than optical protection by
tanning.
One of the reasons for our joint study with Hemminki (Bykov et
al, 1999) was to verify our conclusions on repair of cyclobutane
pyrimidine dimers and 6±4 photoproducts in an earlier study
(Young et al, 1996) using antibody techniques. Both studies, using
2 MED of the same source of SSR, showed rapid repair of 6±4
photoproducts and much slower repair of CPD. Young et al (1996)
estimated that the mean half-life of thymine dimers in skin type
I + II was 33.3 h. Bykov et al (1998a) estimated that 50% of
thymine dimers were removed after 32 h after a single exposure to
SSR (skin type not speci®ed). More recently, Bykov et al (1999)
showed a 50% reduction at 17.2 h in skin type II & Xu et al (2000b)
show data (Fig 3) that suggest a 50% reduction of thymine dimers at
about 42 h that is skin type independent. The main conclusion that
can be reached on thymine dimer repair is that it is relatively slow
and shows very large interperson variation. We also observe large
interperson variation in thymine dimer repair capacity. Thus,
different results are likely with different small groups of human
volunteers.
We fully endorse the development of reliable quanti®cation of
DNA photodamage in situ but are puzzled by the unaccountably
large interpersonal variation within a given skin type grouping
when a ®xed UVR dose is given. Such large differences (ranging
from 5 to 30 fold in skin types II/III and I/II, respectively) (Bykov
et al, 2000, 1998b, respectively) on the lower back cannot possibly
be due to variation in constitutive pigmentation related photo-
protection, as suggested by Bykov et al (2000), because Xu et al
(2000b) have shown that the difference in photoproduct levels from
a ®xed SSR dose on previously unexposed buttock skin in skin
types I/II and III/IV is not signi®cant for 3 types of DNA
photolesion (including thymine dimers) and only 1.4 fold greater in
skin types I/II for thymine-cytosine CPD. Hemminki et al (2002)
show that thymine dimers are induced at a signi®cantly higher level
(~ 3 2) on unexposed buttock skin in one study group of skin type
I compared with type IV after a ®xed dose of SSR, yet in a larger
but older study group of skin type I there was no difference
between skin types I and IV. Does this mean that older unexposed
buttock skin becomes less sensitive to DNA photodamage? It seems
improbable that large interperson variation could be due to any
facultative pigmentation on the lower back, especially > 30-fold
variation in skin types I/II (Bykov et al, 1998b). Indeed, Hemminki
et al (1999) have shown that the DNA photodamage protection
factor of UVA-induced pigmentation in fair skinned people is 1.2
but this complete lack of protection is not surprising given the well-
known differences between UVA and UVB induced pigmentation.
A review of pigmentation-related protection factors against DNA
photodamage (Young and Sheehan 2001) shows that they are
probably in the region of 2±3, which cannot explain large
interperson variation of DNA damage induction within a given
skin type. We also note that there is a ~ 30% ± ~56% variation in
repeated analysis of the same samples (Bykov et al, 1998b;
Hemminki et al, 1999) and cannot help but wonder if this
contributes to the somewhat contradictory results given above.
In conclusion, we endorse quantitative techniques but feel that
immunostaining has an important role in the assessment of DNA
photodamage and its repair in human skin, and we totally disagree
with Hemminki and Snellman (2002) that quantitative and
qualitative data obtained with such techniques are unreliable, all
the more so when many of the biological conclusions that we have
reached with our techniques are in broad agreement with those
from Hemminki's laboratory.
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